Continue to site >
Trending ETFs

Vitality Portfolio

mutual fund
MSVDX
Payout Change
Pending
Price as of:
$6.33 -0.03 -0.47%
primary theme
N/A
MSVDX (Mutual Fund)

Vitality Portfolio

Payout Change
Pending
Price as of:
$6.33 -0.03 -0.47%
primary theme
N/A
MSVDX (Mutual Fund)

Vitality Portfolio

Payout Change
Pending
Price as of:
$6.33 -0.03 -0.47%
primary theme
N/A

Name

As of 10/02/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Vitality Portfolio

MSVDX | Fund

$6.33

$2.29 M

0.00%

13.74%

Vitals

YTD Return

-0.8%

1 yr return

9.7%

3 Yr Avg Return

N/A

5 Yr Avg Return

N/A

Net Assets

$2.29 M

Holdings in Top 10

55.5%

52 WEEK LOW AND HIGH

$6.4
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 13.74%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 10/02/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Vitality Portfolio

MSVDX | Fund

$6.33

$2.29 M

0.00%

13.74%

MSVDX - Profile

Distributions

  • YTD Total Return -0.8%
  • 3 Yr Annualized Total Return N/A
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio N/A
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Vitality Portfolio
  • Fund Family Name
    Morgan Stanley Funds
  • Inception Date
    Dec 31, 2021
  • Shares Outstanding
    N/A
  • Share Class
    I
  • Currency
    USD
  • Domiciled Country
    US

Fund Description

Under normal market conditions, the Adviser seeks to achieve the Fund’s investment objective by investing primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. These companies include, but are not limited to, biotechnology, pharmaceuticals, medical equipment and supplies, healthcare technology, healthcare providers and services, and life sciences tools and services. The Fund may also allocate to industries related to the healthcare industry, but are not primarily engaged in the scientific advancement of healthcare. The allocation among these areas will vary depending on the relative potential the Adviser sees within each area and the outlook for the overall healthcare sector.  
The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. In selecting securities for investment, the Adviser typically invests in unique companies it believes have sustainable competitive advantages, strong research and development and productive new product flow, financial strength, and an attractive risk/reward profile. The Fund generally seeks investments in companies that are developing new and effective medicines, enabling novel and more efficient research and development efforts, as well as companies whose business models reduce costs or improve quality in healthcare systems. The Adviser typically focuses a significant portion of the Fund’s investments in a limited number of issuers, which may be in the same industry, sector or geographic region.
The Adviser actively integrates sustainability into the investment process by using environmental, social and governance (“ESG”) factors as a lens for additional fundamental research, which can contribute to investment decision-making. The Adviser seeks to understand how environmental and social initiatives within companies can create value by strengthening durable competitive advantages, creating growth opportunities, driving profitability and/or aligning with secular growth trends. The Adviser generally engages with company management teams to discuss their ESG practices, with the aim of identifying how sustainability themes present opportunities and risks that can be material to the value of the security over the long-term. Other aspects of the investment process include a proprietary, systematic evaluation of governance policies, specifically focusing on compensation alignment on long-term value creation.  Although consideration of ESG factors is incorporated into the investment process, it is only one of many tools the Adviser utilizes to make investment decisions.
The Fund has a fundamental policy (i.e., one that cannot be changed without shareholder approval) of investing 25% or more of its total assets in the group of industries comprising the healthcare sector. Companies in the healthcare sector include biotechnology companies, pharmaceutical companies, medical equipment and supplies, healthcare technology, healthcare providers and services, and life sciences tools and services. Because the Fund is concentrated in the healthcare sector, it is less diversified than stock funds that invest in a broader range of industries and, therefore, the Fund could experience significant volatility.
The Fund will invest primarily in equity securities. The Fund may also invest in privately placed and restricted securities and special purpose acquisition companies.
The Adviser may invest up to 25% of the Fund’s total assets in foreign securities, including emerging market securities and securities classified as American Depositary Receipts (“ADRs”), Global Depositary Receipts (“GDRs”), American Depositary Shares (“ADSs”) or Global Depositary Shares (“GDSs”), foreign U.S. dollar-denominated securities that are traded on a U.S. exchange or local shares of non-U.S. issuers.
The equity securities in which the Fund primarily invests include common and preferred stocks, convertible securities and equity-linked securities, rights, warrants, depositary receipts, limited partnership interests, exchange-traded funds (“ETFs”) and open-end and closed-end investment companies (including those which may be managed by the Adviser or its affiliates) and initial public offerings (“IPOs”).
The Fund may use certain derivatives for the purposes of hedging, risk management, portfolio management or to earn income.
Read More

MSVDX - Performance

Return Ranking - Trailing

Period MSVDX Return Category Return Low Category Return High Rank in Category (%)
YTD -0.8% N/A N/A N/A
1 Yr 9.7% N/A N/A N/A
3 Yr N/A* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Return Ranking - Calendar

Period MSVDX Return Category Return Low Category Return High Rank in Category (%)
2023 9.2% N/A N/A N/A
2022 -41.6% N/A N/A N/A
2021 N/A N/A N/A N/A
2020 N/A N/A N/A N/A
2019 N/A N/A N/A N/A

Total Return Ranking - Trailing

Period MSVDX Return Category Return Low Category Return High Rank in Category (%)
YTD -0.8% N/A N/A N/A
1 Yr 9.7% N/A N/A N/A
3 Yr N/A* N/A N/A N/A
5 Yr N/A* N/A N/A N/A
10 Yr N/A* N/A N/A N/A

* Annualized

Total Return Ranking - Calendar

Period MSVDX Return Category Return Low Category Return High Rank in Category (%)
2023 9.2% N/A N/A N/A
2022 -39.8% N/A N/A N/A
2021 N/A N/A N/A N/A
2020 N/A N/A N/A N/A
2019 N/A N/A N/A N/A

NAV & Total Return History


MSVDX - Holdings

Concentration Analysis

MSVDX Category Low Category High MSVDX % Rank
Net Assets 2.29 M N/A N/A N/A
Number of Holdings 39 N/A N/A N/A
Net Assets in Top 10 1.18 M N/A N/A N/A
Weighting of Top 10 55.52% N/A N/A N/A

Top 10 Holdings

  1. Eli Lilly Co 9.90%
  2. Morgan Stanley Institutional Liquidity Funds - Treasury Securities Portfolio 6.17%
  3. Argenx SE 5.63%
  4. Intuitive Surgical Inc 5.61%
  5. UnitedHealth Group Inc 5.54%
  6. Vertex Pharmaceuticals Inc 5.45%
  7. Alnylam Pharmaceuticals Inc 4.78%
  8. Thermo Fisher Scientific Inc 4.70%
  9. Exact Sciences Corp 4.36%
  10. 10X Genomics Inc 3.37%

Asset Allocation

Weighting Return Low Return High MSVDX % Rank
Stocks
91.86% N/A N/A N/A
Cash
8.79% N/A N/A N/A
Other
0.73% N/A N/A N/A
Preferred Stocks
0.00% N/A N/A N/A
Convertible Bonds
0.00% N/A N/A N/A
Bonds
0.00% N/A N/A N/A

Stock Sector Breakdown

Weighting Return Low Return High MSVDX % Rank
Utilities
0.00% N/A N/A N/A
Technology
0.00% N/A N/A N/A
Real Estate
0.00% N/A N/A N/A
Industrials
0.00% N/A N/A N/A
Healthcare
0.00% N/A N/A N/A
Financial Services
0.00% N/A N/A N/A
Energy
0.00% N/A N/A N/A
Communication Services
0.00% N/A N/A N/A
Consumer Defense
0.00% N/A N/A N/A
Consumer Cyclical
0.00% N/A N/A N/A
Basic Materials
0.00% N/A N/A N/A

Stock Geographic Breakdown

Weighting Return Low Return High MSVDX % Rank
US
91.86% N/A N/A N/A
Non US
0.00% N/A N/A N/A

MSVDX - Expenses

Operational Fees

MSVDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 13.74% N/A N/A N/A
Management Fee 0.75% N/A N/A N/A
12b-1 Fee N/A N/A N/A N/A
Administrative Fee N/A N/A N/A N/A

Sales Fees

MSVDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A N/A N/A N/A
Deferred Load N/A N/A N/A N/A

Trading Fees

MSVDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A N/A N/A N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

MSVDX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A N/A N/A N/A

MSVDX - Distributions

Dividend Yield Analysis

MSVDX Category Low Category High MSVDX % Rank
Dividend Yield 0.00% N/A N/A N/A

Dividend Distribution Analysis

MSVDX Category Low Category High Category Mod
Dividend Distribution Frequency Annual

Net Income Ratio Analysis

MSVDX Category Low Category High MSVDX % Rank
Net Income Ratio N/A N/A N/A N/A

Capital Gain Distribution Analysis

MSVDX Category Low Category High Capital Mode
Capital Gain Distribution Frequency

Distributions History

View More +

MSVDX - Fund Manager Analysis

Tenure Analysis

Category Low Category High Category Average Category Mode
N/A N/A N/A N/A